PLoS Medicine (Dec 2019)

Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study.

  • Elisé G Kaboré,
  • Charles Guenancia,
  • Ines Vaz-Luis,
  • Antonio Di Meglio,
  • Barbara Pistilli,
  • Charles Coutant,
  • Paul Cottu,
  • Anne Lesur,
  • Thierry Petit,
  • Florence Dalenc,
  • Philippe Rouanet,
  • Antoine Arnaud,
  • Olivier Arsene,
  • Mahmoud Ibrahim,
  • Johanna Wassermann,
  • Geneviève Boileau-Jolimoy,
  • Anne-Laure Martin,
  • Jérôme Lemonnier,
  • Fabrice André,
  • Patrick Arveux

DOI
https://doi.org/10.1371/journal.pmed.1002989
Journal volume & issue
Vol. 16, no. 12
p. e1002989

Abstract

Read online

BackgroundIn patients treated with cardiotoxic chemotherapies, the presence of cardiovascular risk factors and previous cardiac disease have been strongly correlated to the onset of cardiotoxicity. The influence of overweight and obesity as risk factors in the development of treatment-related cardiotoxicity in breast cancer (BC) was recently suggested. However, due to meta-analysis design, it was not possible to take into account associated cardiac risk factors or other classic risk factors for anthracycline (antineoplastic antibiotic) and trastuzumab (monoclonal antibody) cardiotoxicity.Methods and findingsUsing prospective data collected from 2012-2014 in the French national multicenter prospective CANTO (CANcer TOxicities) study of 26 French cancer centers, we aimed to examine the association of body mass index (BMI) and cardiotoxicity (defined as a reduction in left ventricular ejection fraction [LVEF] > 10 percentage points from baseline to LVEF ConclusionsIn BC patients, obesity appears to be associated with an important increase in risk-related cardiotoxicity (CANTO, ClinicalTrials.gov registry ID: NCT01993498).Trial registrationClinicalTrials.gov NCT01993498.